Although molecular diagnostics are highly sensitive in the diagnosis of fluroquinolone 18 (FQ)-resistant tuberculosis (TB), the discordant results with the sequential phenotypic 19 drug susceptibility testing (DST) invariably occur. To investigate the prevalence and 20 the cause of discordant results between molecular and phenotypic DST for 21 levofloxacin (LFX), the cases who were determined to be LFX-susceptible using the 22 2 phenotypic DST but LFX-resistant using the MeltPro assay were retrospectively 23 reviewed in Beijing, China. We measured LFX minimal inhibitory concentrations 24 (MICs) using Middlebrook 7H9 broth. Sanger sequencing was used to determine 25 genotypic characteristics of discordant isolates. Between January and December 2018, 26 126 (22.1%) out of 571 smear-positive TB patients were identified as LFX-resistant 27 TB by MeltPro assay. Among the 126 LFX-resistant TB, there were 34 isolates 28 identified as LFX-susceptible TB by phenotypical DST. This result demonstrated a 29 discordance prevalence of 27.0%. LFX MICs were majorly centered around the 30 critical concentration, and 7 (21.2%) and 13 (39.4%) had MICs of 2.0 mg/l and 4.0 31 mg/l, respectively. The most prevalent mutations conferring discordant LFX 32 resistance were the amino acid substitutions of Ser to Leu in 90 codon (13, 39.4%) 33 and Asp to Ala in 94 codon of gyrA (11, 33.3mg/l belonged to Ala90Val and 34 Asp94Ala group. In conclusion, our data demonstrate that more than one quarter of 35 LFX-resistant isolates by molecular method are susceptible to LFX using the 36 phenotypic DST. The high prevalence of discordant LFX resistance is majorly due to 37 the isolates with specific mutations within gyrA gene conferring proximity of MICs to 38 the critical concentration. 39 gyrA 41 42 126 The PCR mixture were prepared as follows: 25 μl 2×PCR Mixture, 2 μl of DNA 127 template and 0.2 μM of each primer set. After completion of the thermal cycler 128 program, the amplicons were sent to Tsingke Company (Beijing, China) for DNA 129 sequencing service. DNA sequences were compared with the homologous sequences 130 of MTB H37Rv strain to identify whether the sequences had genetic mutations within 131 QRDR. 132 7 133
INTRODUCTION
Despite the great achievements in tuberculosis (TB) control globally, the epidemic of 44 3 drug-resistant tuberculosis, especially multidrug-resistant tuberculosis (MDR-TB), 45 poses a major barrier to eliminate TB (1, 2) . In 2018, the World Health Organization 46 (WHO) estimates that 48, 400 MDR/RR-TB cases have occurred worldwide, only 32% 47 of which were successfully diagnosed and treated (2). Therefore, rapid and accurate 48 laboratory diagnosis of drug susceptibility of MTB is essential to ensure early 49 initiation of appropriate treatment for drug-resistant TB patients, thus preventing 50 further transmission in the community (3, 4) . and clinical management dilemmas (9). Understanding the interpretation of these 67 discordant results is thus important to ensure optimal diagnosis and treatment.
69
Fluroquinolones (FQs) are cornerstone drugs in the treatment of MDR-TB (10). The 70 subunit A of gyrase (gyrA) is the primary target of current FQs in MTB, thus killing 71 bacteria via inhibiting DNA supercoiling and disrupting DNA replication (11, 12) .
72
Thus, the mutations located in gyrA gene are considered as an alternative for 73 predicting FQ resistance in MTB (12). In China, the MeltPro TB assay (MeltPro, 74 Zenssen, China) is the only commercial molecular test approved for the diagnosis of 75 FQ-resistant TB, and also widely used in clinical practice since 2018 (13). However, 76 limited knowledge is available to examined the prevalence of false-positive results 77 between molecular and phenotypic DST for FQs. To address this concern, we 78 retrospectively reviewed the cases who were determined to be levofloxacin The MeltPro assay testing was performed as previously described ( Fig. 1) (13) . In drug concentrations tested were doubling dilution, ranging from 0.063 to 64 mg/l.
114
Plates were incubated at 37°C in 5% CO 2 for one week. Then 70 μl of AlamarBlue 115 and 5% Tween80 2:5 mixed solution was added to each well, incubated for 24 h at 116 37°C, and assessed for color development. As a consequence of bacterial growth, the 117 oxidation-reduction indicator AlamarBlue changed color from blue to pink (15). The
118
MIC was defined as the lowest concentration of drug that prevented the color change 119 from blue to pink. The reference MTB strain H37Rv (ATCC 27249) was tested in 120 both rounds for quality control purpose. exclusion of one isolate due to subculture failure, a total of 33 discordant isolates 139 from 33 patients were further analyzed. As showed in Table 1 , the isolates displayed a DNA sequencing data revealed that the most prevalent mutations conferring 145 discordant FQ resistance were the amino acid substitutions of Ser to Leu in 90 codon 146 (13, 39.4%) and Asp to Ala in 94 codon of gyrA (11, 33.3%), respectively. Mutations 147 Thr91Pro (n = 1), Asp94Gly (n = 1), Asp94Val (n = 1), Asp94Tyr (n = 1) and Asp94Asn 148 (n = 1) were detected in five separate isolates. In addition, two heteroresistant isolates 149 were identified by Sanger sequencing plots. In one isolate, the mutant G allele in 94 150 codon of gyrA (94Gly) was mixed with the wild-type A allele (94Asp) (Fig. 3A) .
151
Double point mutations were observed in the other heteroresistant isolate carrying 152 both the Thr91Pro and Asp94Gly mutations (Fig. 3B) . Notably, two FQ-resistant 153 isolates reported by MeltPro assay had no mutation within gyrA gene by DNA 154 8 sequencing. By re-examination of MeltPro patterns, we found that both these isolates 155 had two melting curve peaks (Fig. 4) , representing the simultaneous presence of 156 mutant and the wild type in the specimens. Table 2 . 18 of these isolates were confirmed to be resistant to LFX by using 160 2.0 mg/l as cut-off value, and the remaining 15 isolates were susceptible to LFX. The
161
LFX MICs for MTB isolates with the mutation Ala90Val ranged from 2.0 to 8.0 mg/l.
162
In addition, the lower LFX values were observed for Asp94Ala mutants, ranging from phenotypically LFX-susceptible. The high rate found in this study may be majorly 175 due to the fact we used broth-based assays for drug susceptibility testing instead of the 176 9 solid agar-based methods, which are more likely to identify the drug-resistant MTB 177 isolates with low-level resistance (19) . In addition, although phenotypical DST is 178 considered as gold standard for detection of in vitro drug susceptibility, there is 179 increasing evidence that the low-level resistance is associated with a marked decrease 180 in reproducibility of this phenotypical method, even in the sophisticated laboratories 181 (8, 20) . As a consequence, the isolates with MICs that is very close or equal to the 182 defined critical concentration for the tested drug are prone to be missed. These 183 isolates are termed "challenging isolates", as they are responsible for the majority of 184 discordant results between phenotypical and genotypical method. It is well known that various gyrA mutations are associated with different levels of 200 resistance to LFX (11). In consistent to previous findings, we found that the MICs of 201 isolates with either Ala90Val or Asp94Ala mutation are scattered around the critical 202 concentrations of LFX (11, 23) . In a previous retrospective study, the treatment failure 203 with FQ-containing regimen was reported in patients infected with isolates harboring 204 these mutations, suggesting that they are probable resistant to FQ (24), but may be We also acknowledge the limitations in the study. First, the major limitation is the 234 small sample size in our analysis. The first commercial kit for detecting FQ 235 susceptibility, MeltPro TB assay, was approved by Chinese FDA in 2018. Hence, the 236 short-term application of this method become the major barrier to recruit more cases.
237
Further study will be carried to validate our conclusion in larger samples. Second, the 238 discordant LFX susceptibility was not assessed by another phenotypic DST method. It 239 is difficult to compare the capability of different phenotypic methods to detect 240 low-level LFX resistance. Third, the clinical outcomes of these cases with discordant 241 LFX susceptibility were not evaluated due to the high proportion of loss to follow-up. In conclusion, our data demonstrate that more than one quarter of LFX-resistant 244 isolates by molecular method are susceptible to LFX using the phenotypic DST. The The two isolates both had two melting curve peaks in the melting curve, indicating the 351 occurrence of wide-type and mutant gyrA gene in the initial specimens. 
